These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32996844)

  • 21. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
    DiMondi VP; Drew RH; Chen LF
    Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
    Rank DR; Friedland HD; Laudano JB
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
    Noel GJ
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():25-9. PubMed ID: 17488373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
    Lagacé-Wiens PR; Rubinstein E
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a 
    Welte T; Scheeren TW; Overcash JS; Saulay M; Engelhardt M; Hamed K
    Future Microbiol; 2021 May; 16():543-555. PubMed ID: 33960817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
    Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients.
    Rubino CM; Polak M; Schröpf S; Münch HG; Smits A; Cossey V; Tomasik T; Kwinta P; Snariene R; Liubsys A; Gardovska D; Hornik CD; Bosheva M; Ruehle C; Litherland K; Hamed K
    Pediatr Infect Dis J; 2021 Nov; 40(11):997-1003. PubMed ID: 34533489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
    File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
    Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
    Fogarty CM; Cyganowski M; Palo WA; Hom RC; Craig WA
    Clin Ther; 2002 Nov; 24(11):1854-70. PubMed ID: 12501879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis.
    Eljaaly K; Wali H; Basilim A; Alharbi A; Asfour HZ
    Int J Antimicrob Agents; 2019 Aug; 54(2):149-153. PubMed ID: 31173864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia.
    Montravers P; Harpan A; Guivarch E
    Adv Ther; 2016 Feb; 33(2):151-66. PubMed ID: 26861846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftobiprole: a new broad spectrum cephalosporin.
    El Solh A
    Expert Opin Pharmacother; 2009 Jul; 10(10):1675-86. PubMed ID: 19527192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftobiprole mono-therapy versus combination or non-combination regimen of standard antibiotics for the treatment of complicated infections: A systematic review and meta-analysis.
    Jame W; Basgut B; Abdi A
    Diagn Microbiol Infect Dis; 2024 Jul; 109(3):116263. PubMed ID: 38615599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Dauner DG; Nelson RE; Taketa DC
    Am J Health Syst Pharm; 2010 Jun; 67(12):983-93. PubMed ID: 20516468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
    Noel GJ; Strauss RS; Amsler K; Heep M; Pypstra R; Solomkin JS
    Antimicrob Agents Chemother; 2008 Jan; 52(1):37-44. PubMed ID: 17954698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is gentamicin safe and effective for severe community-acquired pneumonia? An 8-year retrospective cohort study.
    Brereton CJ; Lennon D; Browning S; Dunn E; Ferguson JK; Davis JS
    Int J Antimicrob Agents; 2018 Jun; 51(6):862-866. PubMed ID: 29410326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia.
    Batard E; Lecadet N; Goffinet N; Hardouin JB; ; Lepelletier D; Potel G; Montassier E
    Infection; 2015 Dec; 43(6):681-9. PubMed ID: 25998004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Vidaillac C; Rybak MJ
    Pharmacotherapy; 2009 May; 29(5):511-25. PubMed ID: 19397461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.